To gain insight into the levels of OXPHOS and glycolysis in melanoma cells, we initially evaluated the levels of OXPHOS complexes and voltage-dependent anion-selective channel 1 (VDAC1) (as a marker for mitochondrial mass) in four melanoma cell lines with mutations affecting BRAF or NRAS or neither oncogene—BRAF and NRAS wild-type (WM3311), BRAF-mutated (WM47 and A375), and NRAS-mutated (WM3000)—and compared them to HDFs as non-cancerous skin cells. Here, BRAF is linked to melanoma.